Factors influencing macrophage activation by muramyl peptides: inhibition of NO synthase activity by high levels of NO.
Treatment with muramyldipeptide (MDP) or a lipophilic derivative (MTP-Chol) included in nanocapsules renders macrophages cytostatic towards tumor cells. At the same time, nitric oxide (NO) synthase (EC 1.14.23) activity is induced, as determined by measurement of the two end products of the reaction (nitrite and L-citrulline). The objective of this study was to investigate some factors which might influence this activation and explain the decreased response observed at high nanocapsule concentrations. The glucose content of the medium did not seem to be limiting. Addition of indomethacin decreased nitrite production in the effector phase, suggesting a role for prostaglandins in the maintenance of the activated state. We also tested the hypothesis that NO itself might regulate inducible nitric oxide synthase activity. The addition of NO donors (SIN-1 and nitrosoglutathione) or superoxide dismutase to cultures of activated macrophages inhibited the NO synthase activity. Since these NO donors were non toxic towards macrophages, these observations indicate clearly that the addition of exogenous NO to that formed by the enzymatic reaction can cause inhibition of the inducible NO synthase.
Morin
C
C
Laboratoire de Pharmacotechnie-Biopharmacie, URA CNRS 1218, Université de Paris Sud, Faculté de Pharmacie, Châtenay-Malabry, France.
Fessi
H
H
Devissaguet
J P
JP
Puisieux
F
F
Barratt
G
G
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology*; D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors*; D000818:Animals; D005260:Female; D008262:Macrophage Activation / Q000187:drug effects*; D016676:Macrophages, Alveolar / Q000187:drug effects; D009569:Nitric Oxide / Q000502:physiology*; D019001:Nitric Oxide Synthase; D051381:Rats; D017208:Rats, Wistar
D009569:Nitric Oxide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases